ArticleArchives of women's mental health2024

Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS).

Meilian Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.